IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1)

摘要

FIELD: biotechnology.;SUBSTANCE: disclosed are isolated antibodies and antigen-binding fragments thereof, specifically binding programmed cell death protein ligand 1 (PD-L1), coding nucleic acids thereof, as well as vectors and host cells for producing said antibodies. Also disclosed is a pharmaceutical composition, an immunoconjugate and a fusion protein comprising the disclosed antibodies. Invention also relates to methods of treating PD-1 mediated diseases.;EFFECT: antibodies to PD-L1 have high affinity to PD-L1, perform the function of PD-L1 inhibition, have less immunogenicity compared to their unmodified parental antibodies in this biological species, are able to increase T-cell proliferation and IL-2 secretion in a mixed lymphocytic reaction.;22 cl, 8 tbl, 4 ex